Amivantamab has already received regulatory approval for patients with NSCLC with exon 20 insertions18, and it is currently being investigated together with lazertinib (a third generation EGFR inhibitor approved in Korea for EGFR T790M+ patients as a second line treatment19) in the multi-cohort basket trial CHRYSALIS-2 (NCT04077463). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.